ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology
Novartis India Ltd · Press Release · 04 Nov 2026, 1:31 am
ChrysCapital Takes Control of Evonile Pharma; Expands into Cardiology and Ophthalmology Following ChrysCapital's acquisition of a controlling 70.68% stake, Evonile Pharma (formerly Novartis India) reported its Q2 FY27 and H1 FY27 results under a revamped direct-distribution business model. Q2 FY27 revenue from operations reached ₹56.1 crore, while operating EBITDA stood at -₹31.8 crore due to upfront investments and one-time transition costs. For H1 FY27, revenue stood at ₹159.9 crore with a net loss of ₹45.3 crore. Strategically, the company expanded beyond its core therapy areas by acquiring Minipress XL (cardiology) and entering into an ophthalmology in-licensing agreement.
Original exchange filing (PDF)
More announcements from Novartis India Ltd
- Transcript of the Earnings Call held on Wednesday, November 04, 2026. · 06 Nov 2026
- Submission of the Letter of Offer in connection with the proposed Rights Issue of the Partly Paid-up Equity Shares of the Company. · 06 Nov 2026
- Intimation is hereby given that the record date for determining the rights entitlement for the Rights Issue of partly paid-up shares of the Company shall be Wednesday, November 11, 2026. · 05 Nov 2026
- Outcome of the Board Meeting held today i.e. November 04, 2026 · 05 Nov 2026
- Outcome of the meeting of the Rights Issue Committee held today i.e. November 04, 2026 · 05 Nov 2026
- Intimation of the Audio Recording of the Earnings Call for the Unaudited Financial Results for the quarter and half year ended September 30, 2026, held today i.e. on Wednesday, November 04, 2026. · 04 Nov 2026
- Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026. · 04 Nov 2026
- Submission of Investor Presentation for the Earnings Call scheduled on Wednesday, November 04, 2026. · 04 Nov 2026
